0001209191-24-001449.txt : 20240111 0001209191-24-001449.hdr.sgml : 20240111 20240111161819 ACCESSION NUMBER: 0001209191-24-001449 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240105 FILED AS OF DATE: 20240111 DATE AS OF CHANGE: 20240111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carulli Michael CENTRAL INDEX KEY: 0002006668 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39539 FILM NUMBER: 24529465 MAIL ADDRESS: STREET 1: C/O PMV PHARMACEUTICALS, INC. STREET 2: ONE RESEARCH WAY CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001699382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 463218129 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE RESEARCH WAY CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 642-6664 MAIL ADDRESS: STREET 1: ONE RESEARCH WAY CITY: PRINCETON STATE: NJ ZIP: 08540 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2024-01-05 0 0001699382 PMV Pharmaceuticals, Inc. PMVP 0002006668 Carulli Michael C/O PMV PHARMACEUTICALS, INC. ONE RESEARCH WAY PRINCETON NJ 08540 0 1 0 0 Chief Financial Officer Common Stock 9066 D Employee Stock Option (right to buy) 4.22 2030-06-02 Common Stock 24632 D Employee Stock Option (right to buy) 28.33 2031-05-12 Common Stock 13605 D Employee Stock Option (right to buy) 16.29 2032-02-10 Common Stock 27200 D Employee Stock Option (right to buy) 5.70 2033-05-12 Common Stock 75000 D The shares are represented by restricted stock units which vest on September 9, 2024. An option to purchase 28,489 shares was granted on June 2, 2020 and was exercised in part prior to the date on which the reporting person became subject to Section 16. One-fourth of the shares subject to the option vested on May 26, 2021, and the remaining shares vest in 36 equal monthly installments beginning on June 26, 2021. Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021. Shares subject to the option vest in 48 equal monthly installments beginning on March 10, 2022. Shares subject to the option vest in 48 equal monthly installments beginning on June 12. 2023. /s/ Robert Ticktin, by power of attorney 2024-01-11 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                POWER OF ATTORNEY

      The undersigned, as a Section 16 reporting person of PMV Pharmaceuticals,
Inc. (the "Company"), hereby constitutes and appoints David H. Mack, Ph.D.,
and Robert Ticktin, and each of them, as the undersigned's true and
lawful attorney-in-fact to:

      1. complete and execute Forms 3, 4 and 5 and other forms and all
amendments thereto as such attorney-in-fact shall in his discretion
determine to be required or advisable pursuant to Section 16 of the Securities
Exchange Act of 1934 (as amended) and the rules and regulations promulgated
thereunder, or any successor laws and regulations, as a consequence of the
undersigned's ownership, acquisition or disposition of securities of the
Company; and

      2. do all acts necessary in order to file such forms with the SEC,
any securities exchange or national association, the Company and such other
person or agency as the attorneys-in-fact shall deem appropriate.

      The undersigned hereby ratifies and confirms all that said attorneys-in-
fact and agents shall do or cause to be done by virtue hereof.  The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16
of the Securities Exchange Act of 1934 (as amended).

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of December 31, 2023.

      				Signature: /s/  Michael Carulli
      				Print Name:	Michael Carulli